Literature DB >> 10529126

Compliance to drug treatment of patients with rheumatoid arthritis: a 3 year longitudinal study.

F Viller1, F Guillemin, S Briançon, T Moum, T Suurmeijer, W van den Heuvel.   

Abstract

OBJECTIVE: Patient compliance is considered necessary for the success of drug treatment in chronic diseases. We document compliance with drug treatment and the factors affecting it in a cohort of patients with rheumatoid arthritis (RA).
METHODS: A prospective cohort study of 556 patients with RA followed for 3 years in 4 counties: Oslo, Norway; Groningen, The Netherlands; and Nancy and Reims, France. Compliance to treatment was assessed annually by interview in terms of adherence to the dose and timing of the prescribed drug regimen.
RESULTS: Of the 556 subjects, 429 (77.2%) were taking medication for RA throughout the observation period. Consistent behavior was recorded in 59.5% of cases: 35.7% were consistently compliant, and 23.8% consistently noncompliant. Factors significantly associated with good compliance were older age (p = 0.00), female sex (p = 0.03), decreased disability (p = 0.04), very satisfactory contacts with health care professionals (p = 0.03), and more personal knowledge about the disease and its treatment (p = 0.03).
CONCLUSION: This longitudinal study identified compliance behavior as consistent over time in 60% of patients, determined by quality of contact with professionals and the amount of patient information available.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529126

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  62 in total

1.  A multicenter study of the predictors of adherence to self-injected glatiramer acetate for treatment of relapsing-remitting multiple sclerosis.

Authors:  Howard Zwibel; Gabriel Pardo; Shelly Smith; Douglas Denney; Merrikay Oleen-Burkey
Journal:  J Neurol       Date:  2010-10-06       Impact factor: 4.849

Review 2.  The role of human factors in the design and development of an insulin pump.

Authors:  Noel E Schaeffer
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

3.  Exploring the Relationship Between Patient Activation, Treatment Satisfaction, and Decisional Conflict in Patients Approaching End-Stage Renal Disease.

Authors:  Miriam Vélez-Bermúdez; Alan J Christensen; Ellen M Kinner; Anne I Roche; Mony Fraer
Journal:  Ann Behav Med       Date:  2019-08-16

4.  Qualitative assessment of medication adherence in patients with rheumatic diseases on biologic therapy.

Authors:  Sudha Raghunath; Raif Hijjawi; Elizabeth Hoon; E Michael Shanahan; Fiona Goldblatt
Journal:  Clin Rheumatol       Date:  2019-06-06       Impact factor: 2.980

5.  Compliance with treatment of rheumatoid arthritis.

Authors:  Raili Müller; Riina Kallikorm; Kaja Põlluste; Margus Lember
Journal:  Rheumatol Int       Date:  2011-09-24       Impact factor: 2.631

Review 6.  Medication adherence in patients with rheumatoid arthritis: why do patients not take what we prescribe?

Authors:  Peter K K Wong
Journal:  Rheumatol Int       Date:  2016-09-24       Impact factor: 2.631

Review 7.  Medication non-adherence in the elderly: how big is the problem?

Authors:  Carmel M Hughes
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

8.  Rate and causes of noncompliance with disease-modifying antirheumatic drug regimens in patients with rheumatoid arthritis.

Authors:  Wanruchada Katchamart; Pongthorn Narongroeknawin; Ngamsiree Sukprasert; Wanwisa Chanapai; Ananya Srisomnuek
Journal:  Clin Rheumatol       Date:  2020-09-21       Impact factor: 2.980

9.  Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: associated factors and relationship with disease activity and with disability.

Authors:  Virginia Pascual-Ramos; Irazú Contreras-Yáñez; Antonio R Villa; Javier Cabiedes; Marina Rull-Gabayet
Journal:  Arthritis Res Ther       Date:  2009-02-19       Impact factor: 5.156

Review 10.  Does route of administration affect the outcome of TNF antagonist therapy?

Authors:  Sergio Schwartzman; G James Morgan
Journal:  Arthritis Res Ther       Date:  2004-06-21       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.